MedTrace Logo

Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

NCT02163720 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2020-09-30

No results posted yet for this study

Summary

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

Conditions

Interventions

DRUG

Yondelis®-Caelyx®

Observation of Yondelis®-Caelyx® administration

Sponsors & Collaborators

  • PharmaMar

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Frédéric SELLE, MD · Hôpital Tenon

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-10
Primary Completion
2017-03-31
Completion
2018-09-18

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02163720 on ClinicalTrials.gov